NCT01565096View on ClinicalTrials.gov

Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

PHASE4UnknownINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2012

Conditions
Diabetes Mellitus Type II
Interventions
DRUG

Metformin

Metformin 1000 mg BID

DRUG

Metformin

Metformin 1000 mg BID

DRUG

Vildagliptin

Vildagliptin 50 mg twice daily

DRUG

Glimepiride

Glimepiride at individual dose

Trial Locations (1)

55116

RECRUITING

ikfe GmbH, Mainz

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

IKFE Institute for Clinical Research and Development

OTHER

lead

ikfe-CRO GmbH

INDUSTRY

NCT01565096 - Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy | Biotech Hunter | Biotech Hunter